Figure 2.
Manhattan plots of the relationship between single nucleotide polymorphism (SNP) genotype and any toxicity. Patients treated with (A) FOLFOX (n = 385), (B) FOLFOX + cetuximab (n = 360), (C) XELOX (n = 707) and (D) XELOX + cetuximab (n = 348). The red line indicates a genome-wide significance threshold of P = 5.0 × 10−8 and the blue line indicates a suggestive significance threshold of P = 1.0 × 10−5 [Color figure can be viewed at wileyonlinelibrary.com]
